Le Lézard
Classified in: Environment, Science and technology, Business
Subject: ACC

Aker ASA: Ex-dividend NOK 15.00 today


OSLO, Norway, Nov. 7, 2023 /PRNewswire/ -- The shares in Aker ASA will be traded ex-dividend NOK 15.00 as from today, 7 November 2023.

Media contact
Atle Kigen, Head of Media Relations and Public Affairs Aker ASA
Tel: +47 90 78 48 78
E-mail: [email protected]

Investor contact
Fredrik Berge, Head of Investor Relations Aker ASA
Tel: +47 45 03 20 90
E-mail: [email protected]

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.


These press releases may also interest you

at 19:04
X Financial Files Annual Report on Form 20-F for Fiscal Year 2023
X Financial (the "Company"), a leading online personal finance company in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission ("SEC") on April 29,...

at 19:00
CEAT Specialty's Australian Distributors Join the IPL Frenzy in India
CEAT Specialty hosted the Achievers Meet 2024, aimed to fortify bonds with Australian channel partners, featuring an immersive IPL match experience at Delhi's Arun Jaitley Stadium. Amidst the charged atmosphere on April 27th, attendees witnessed the...

at 18:55
Voxtur Announces Financial Results for the Year and Quarter Ended December 31, 2023
Voxtur Analytics Corp. ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced its financial results for the three months and year ended December 31,...

at 18:45
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...

at 18:45
Pond Technologies Holdings Inc. Announces Filing of 2023 Audited Financial Statements and MD&A
Pond Technologies Holdings Inc. (the "Corporation" or "Pond")  announces the filing of the audited consolidated financial statements of the Corporation for the twelve months ended December 31, 2023 and the related management's discussion and analysis...

More news about Science and technology...


News published on and distributed by: